Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: A case report

Research output: Contribution to journalArticlepeer-review

Abstract

Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalFuture Oncology
Volume15
Issue number24s
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • cardiological comorbidity
  • lenvatinib
  • papillary thyroid cancer
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: A case report'. Together they form a unique fingerprint.

Cite this